Increasing the levels of a tiny RNA molecule known as microRNA-483 enhanced the function of endothelial cells and eased the symptoms…
Articles by Patricia Inácio, PhD
Six weeks of treatment with levosimendan significantly lowered pressure on the heart and improved physical capacity among people with…
Changes in the epigenetic profile — a collection of marks that turn genes on and off — of pulmonary arterial…
Kalytera Therapeutics intends to acquire Salzman Group, a company developing R-107 — a liquid form of nitric oxide —…
United Therapeutics has temporarily stopped enrolling patients in ongoing clinical trials of treprostinil-based therapies for pulmonary arterial hypertension (PAH) amid the …
United Therapeutics’ Orenitram (treprostinil) improves heart function and lowers risk status in people with pulmonary arterial hypertension (PAH) who had…
Small vesicles, called exosomes, released by mesenchymal stem cells helped to ease vascular remodeling in a rat model of…
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However,…
Men with pulmonary arterial hypertension (PAH) are more likely to carry mutations in the BMPR2 gene, a known genetic…
The buildup in the lungs and plasma of oxidized low-density lipoproteins, or LDLs — one of the major vehicles…
Minimal incisions, shorter hospital stays, and faster recovery are some of the advantages of robotic heart surgery to repair a…
Preliminary data from the Phase 2 HELP study testing levosimendan as a potential treatment for pulmonary hypertension (PH) patients with heart failure and…